Filing Details

Accession Number:
0001209191-12-039212
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-07-26 20:59:13
Reporting Period:
2012-07-24
Filing Date:
2012-07-26
Accepted Time:
2012-07-26 19:59:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1544116 Durata Therapeutics Inc. DRTX Pharmaceutical Preparations (2834) 871247903
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1419148 Canaan Viii Lp C/O Canaan Partners,
285 Riverside Avenue, Suite 250
Westport CT 06880
Yes No Yes No
1552200 Canaan Partners Viii Llc C/O Canaan Partners,
285 Riverside Avenue, Suite 250
Westport CT 06880
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-07-24 1,346,475 $0.00 1,346,475 No 4 C Direct
Common Stock Acquisiton 2012-07-24 555,555 $9.00 1,902,030 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2012-07-24 10,771,804 $0.00 1,346,475 $0.00
Common Stock Stock Option (right to buy) Acquisiton 2012-02-28 6,250 $0.00 6,250 $2.08
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
6,250 2022-02-27 No 4 A Indirect
Footnotes
  1. The Series A Preferred Stock has no expiration date and each share of Series A Preferred Stock converted automatically into 0.125 shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration.
  2. Shares held directly by Canaan VIII L.P ("Canaan L.P."). Canaan Partners VIII LLC ("Canaan LLC"), the general partner of Canaan L.P., may be deemed to share voting, investment and dispositive power with respect to shares held by Canaan L.P., but disclaims beneficial ownership of the securities held by Canaan L.P. except to the extent of any pecuniary interest therein.
  3. Mr. Brenton K. Ahrens, a member and manager of Canaan LLC and a vice-president of Canaan Management, Inc. ("Canaan Management", and together with Canaan L.P. and Canaan LLC, the "Canaan Entities"), serves as the representative of the Canaan Entities on the Issuer's board of directors.
  4. This option was granted on February 28, 2012 to Mr. Ahrens with respect to 6,250 shares of common stock, vesting in 36 substantially equal monthly installments over a three year period, the first installment of which vested on March 28, 2012.
  5. Mr. Ahrens, pursuant to an agreement with Canaan Management, is contractually obligated to assign any remuneration received for service as a director to Canaan Management. Each of the Canaan Entities disclaims beneficial ownership in the stock options held by Mr. Ahrens, except to the extent, if any, of its pecuniary interest therein.